Breast cancer is the second leading cause of cancer deaths in the U.S. and worldwide, pointing to the continuing need to improve treatment strategies and therapies that better patient survival and reduce long-term treatment-related toxicities. This is particularly true for aggressive breast cancer subtypes in which many patients are cured of their disease, but at the expense of long-lasting, serious complications, including peripheral neuropathy, adrenal insufficiency, therapy-related leukemia and long-term heart damage.